File(s) under permanent embargo
Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators
journal contributionposted on 2023-05-20, 19:53 authored by Madhur ShastriMadhur Shastri, Chong, WC, Dua, K, Gregory PetersonGregory Peterson, Rahul PatelRahul Patel, Mahmood, MQ, Tambuwala, M, Chellappan, DK, Hansbro, NG, Shukla, SD, Hansbro, PM
Asthma is a common, heterogeneous and serious disease, its prevalence has steadily risen in most parts of the world, and the condition is often inadequately controlled in many patients. Hence, there is a major need for new therapeutic approaches. Mild-to-moderate asthma is considered a T-helper cell type-2-mediated infammatory disorder that develops due to abnormal immune responses to otherwise innocuous allergens. Prolonged exposure to allergens and persistent infammation results in myofbroblast infltration and airway remodelling with mucus hypersecretion, airway smooth muscle hypertrophy, and excess collagen deposition. The airways become hyper-responsive to provocation resulting in the characteristic wheezing and obstructed airfow experienced by patients. Extensive research has progressed the understanding of the underlying mechanisms and the development of new treatments for the management of asthma. Here, we review the basis of the disease, covering new areas such as the role of vascularisation and microRNAs, as well as associated potential therapeutic interventions utilising reports from animal and human studies. We also cover novel drug delivery strategies that are being developed to enhance therapeutic efcacy and patient compliance. Potential avenues to explore to improve the future of asthma management are highlighted.
Department/SchoolSchool of Pharmacy and Pharmacology
PublisherKluwer Academic Publishers
Place of publicationSwitzerland
Rights statementCopyright 2020 Springer Nature Switzerland AG